Biogen
Pharmaceutical company
Follow Biogen on Notably News to receive short updates to your email — rarely!
| 2023 | Biogen experiences continued revenue reduction to $9,835 million and net income drops to $1,161 million |
| 2022 | Continued challenges with revenue further declining to $10,173 million, though net income improves to $3,046 million |
| September 2022 | Biogen agreed to pay $900 million to U.S. federal governments, states, and a whistleblower to settle legal action related to its illegal marketing practices from 2009-2014. |
| 2021 | Significant drop in revenue to $10,981 million and net income reduced to $1,556 million |
| 2020 | Biogen experiences slight revenue decline to $13,445 million but increases employee count to 9,100, potentially due to COVID-19 pandemic impacts |
| 2019 | Company achieves peak revenue of $14,378 million and highest net income of $5,889 million to date |
| 2018 | Biogen reaches 7,800 employees and reports revenue of $13,453 million with a significant net income of $4,431 million |
| 2016 | SPINRAZA was approved as the first drug for treating spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals. |
| 2015 | Company continues strong performance with revenue of $10,764 million and net income of $3,547 million, while maintaining around 7,350 employees |
| 2014 | ELOCTATE was approved for hemophilia A treatment. |
| 2014 | Biogen concluded its period of illegal doctor bribery to increase prescriptions of multiple sclerosis drugs. |
| 2014 | PLEGRIDY was approved in the United States and Europe for relapsing forms of multiple sclerosis. |
| 2014 | Biogen experiences substantial growth, with revenue increasing to $9,703 million, net income of $2,935 million, and employee count rising to 7,550 |
| 2013 | GAZYVA was approved, becoming the first medicine with the FDA's Breakthrough Therapy Designation. |
| 2013 | Biogen reaches 6,850 employees, with significant growth in revenue to $6,932 million and net income of $1,862 million |
| 2013 | TECFIDERA was approved for treating relapsing forms of multiple sclerosis in the United States. |
| 2011 | RITUXAN was approved for ANCA-Associated Vasculitis. |
| 2011 | FAMPYRA received European approval. |
| 2010 | FAMPYRA was approved for improving walking ability in multiple sclerosis patients. |
| 2010 | Biogen reports revenue of $4,716 million and net income of $1,005 million, with total assets of $8,092 million and stock price at $51.95 |
This contents of the box above is based on material from the Wikipedia article Biogen, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.